2020 POPULAR CABG TRIAL Effect of adding ticagrelor to standard aspirin on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting double-blind, placebo-controlled, multicenter, randomized controlled trial M Objective: To assess whether ticagrelor added to standard aspirin Dimproves SVG patency among patients undergoing coronary artery bypass grafting (CABG) 499 Inclusion criteria: Patients ≥ 21 years who underwent planned patients coronary artery bypass graft surgery with > 1 saphenous vein grafts (SVGs) VS Ticagrelor group (n=249) Placebo group (n=247) PRIMARY OUTCOME 9.6 SVG occlusion at 1 year % 10.1 OR 0.87; 95% CI, 0.49 to 1.55; P=0.64 SECONDARY OUTCOMES 12.9 SVG failure at 1 year % HR 1.04; 95% CI, 0.63 to 1.69 13.0 2.8 All-cause mortality % 0 Conclusion: The addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG LM Willemsen et al. Circulation. 2020;142:1799-1807